{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:26:31Z","timestamp":1761488791459},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T00:00:00Z","timestamp":1319760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0026885","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T20:57:14Z","timestamp":1319835434000},"page":"e26885","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine"],"prefix":"10.1371","volume":"6","author":[{"given":"Allison","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janaki","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,10,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.","volume":"12","author":"A Carr","year":"1998","journal-title":"AIDS"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.","volume":"14","author":"A Carr","year":"2000","journal-title":"AIDS"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00126334-200209010-00007","article-title":"Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study.","volume":"31","author":"E Bernasconi","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/00002030-200105040-00005","article-title":"Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.","volume":"15","author":"M Van der Valk","year":"2001","journal-title":"AIDS"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study.","volume":"17","author":"N Friis-M\u00f8ller","year":"2003","journal-title":"AIDS"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.","volume":"22","year":"2008","journal-title":"AIDS"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1086\/375891","article-title":"Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy.","volume":"37","author":"DP Kotler","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/QAD.0b013e3280adc91e","article-title":"The role of adipokines in relation to HIV lipodystrophy.","volume":"21","author":"L Sweeney","year":"2007","journal-title":"AIDS"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/00002030-199814000-00004","article-title":"Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway.","volume":"12","author":"K Brinkman","year":"1998","journal-title":"AIDS"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.","volume":"18","author":"A Martin","year":"2004","journal-title":"AIDS"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.","volume":"38","author":"GA McComsey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/jac\/dkp071","article-title":"Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.","volume":"63","author":"P Tebas","year":"2009","journal-title":"J Antimicrob Chemo"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1310\/hct0906-407","article-title":"Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).","volume":"9","author":"E Ribera","year":"2008","journal-title":"HIV Clin Trials"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/jac\/dkn097","article-title":"Changes in metabolic toxicity switching from stavudine\/didanosine to tenofovir\/lamivudine \u2013 a Staccato trial sub study.","volume":"61","author":"J Ananworanich","year":"2008","journal-title":"J Antimicrob Chemo"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.","volume":"20","author":"GJ Moyle","year":"2006","journal-title":"AIDS"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e3181aa12d5","article-title":"A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir\/lamivudine or tenofovir\/emtricitabine in HIV-1-infected patients with virological suppression.","volume":"51","author":"E Martinez","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial.","volume":"49","author":"A Martin","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1097\/QAD.0b013e32833f147f","article-title":"Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.","volume":"24","author":"A Martin","year":"2010","journal-title":"AIDS"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","article-title":"An objective case definition of HIV lipodystrophy in HIV-infected adults.","volume":"261","author":"A Carr","year":"2003","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/aje\/kwj111","article-title":"for the FRAM study investigators. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design and sample characteristics.","volume":"163","author":"P Tien","year":"2006","journal-title":"Am J Epidemiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","article-title":"Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients.","volume":"32","author":"K Lichtenstein","year":"2003","journal-title":"J Acquir Immun Defic Synd"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00002030-200301030-00017","article-title":"Tumour necrosis factor-alpha gene-238 G\/A promoter polymorphism associated with a more rapid onset of lipodystrophy.","volume":"17","author":"D Nolan","year":"2003","journal-title":"AIDS"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults.","volume":"352","author":"S Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"42077","DOI":"10.1074\/jbc.M107101200","article-title":"Hyperglycaemia-induced production of acute phase reactants in adipose tissue.","volume":"276","author":"Y Lin","year":"2001","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/QAI.0b013e318189a794","article-title":"Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipodystrophy.","volume":"49","author":"AC Ross","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3851\/IMP1491","article-title":"Endothelial function is impaired in HIV-infected patients with lipodystrophy.","volume":"15","author":"P Masia","year":"2010","journal-title":"Antivir Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/QAD.0b013e3282f4dde7","article-title":"The IL-6 system in HIV-1-infection and in HACART-related fat redistribution syndromes.","volume":"22","author":"M Saumoy","year":"2008","journal-title":"AIDS"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0026885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T06:15:17Z","timestamp":1540275317000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0026885"}},"subtitle":[],"editor":[{"given":"Landon","family":"Myer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,10,28]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,10,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0026885","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,28]]}}}